Market Recap: Beam Therapeutics Inc (BEAM)’s Positive Momentum, Closing at 24.40

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The closing price of Beam Therapeutics Inc (NASDAQ: BEAM) was $24.40 for the day, up 5.13% from the previous closing price of $23.21. In other words, the price has increased by $5.13 from its previous closing price. On the day, 1.11 million shares were traded. BEAM stock price reached its highest trading level at $24.43 during the session, while it also had its lowest trading level at $22.21.


Our analysis of BEAM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.99 and its Current Ratio is at 5.99. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.17.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Upgraded its rating to Overweight and sets its target price to $40 from $38 previously.

On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $35.

Jefferies Downgraded its Buy to Hold on December 08, 2023, whereas the target price for the stock was revised from $75 to $30.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 02 ’24 when Simon Amy sold 16,530 shares for $30.54 per share. The transaction valued at 504,851 led to the insider holds 70,060 shares of the business.

Evans John M. sold 18,102 shares of BEAM for $581,617 on Apr 01 ’24. The CEO now owns 1,058,343 shares after completing the transaction at $32.13 per share. On Apr 01 ’24, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 7,157 shares for $32.13 each. As a result, the insider received 229,954 and left with 86,590 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2008390912 and an Enterprise Value of 998947968. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.56 while its Price-to-Book (P/B) ratio in mrq is 2.20. Its current Enterprise Value per Revenue stands at 2.768 whereas that against EBITDA is -6.209.

Stock Price History:

Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $16.95. The 50-Day Moving Average of the stock is -1.65%, while the 200-Day Moving Average is calculated to be -8.41%.

Shares Statistics:

BEAM traded an average of 1.26M shares per day over the past three months and 884730 shares per day over the past ten days. A total of 81.63M shares are outstanding, with a floating share count of 76.79M. Insiders hold about 6.71% of the company’s shares, while institutions hold 78.67% stake in the company. Shares short for BEAM as of 1715731200 were 14584632 with a Short Ratio of 11.60, compared to 1713139200 on 13173332. Therefore, it implies a Short% of Shares Outstanding of 14584632 and a Short% of Float of 23.22.

Most Popular